Please assess the completion status of the following clinical trial:

Trial Title: MEDIHONEY® Gel Versus Collagenase for Wound Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A signed and dated informed consent has been obtained from the subject.~* Subject is able and willing to comply with study procedures.~* Subject is able to comply with weekly visits.~* Subject is 18 years of age or older.~* There is presence of at least 50% or greater necrotic tissue (including slough and eschar) in the wound bed and a total wound surface area of \> 1cm2 to \< 64cm2.~* Subject will not have currently used parenteral or oral antibiotics except for UTI.~* Diabetic subjects: HbA1c \< 12.0 % within 90 days preceding enrollment.~* Pre-albumin greater than 16 mg/dl within 90 days preceding enrollment.~* Subject with a pressure ulcer must be currently receiving adequate pressure redistribution to the affected area via group 2 or 3 specialty bed, a static wheel chair cushion while patient is out of bed.~* Subject with diabetic plantar surface ulcer will use an offloading boot if ambulatory.~* Subject with a venous ulcer must be currently receiving and using compression therapy that can be managed daily.~* Subject and caregiver are trainable and able to perform dressing changes.~* Subject has no allergies to collagenase or honey.~* Subject has no allergies to semi-occlusive or absorptive secondary dressing.~* If subject has multiple wounds only the wound that fits the inclusion criteria will be selected. If more than one wound meets criteria then the largest wound will be selected.~Exclusion Criteria:~* Steroid use \>5mg daily.~* Subject is unable to cooperate with offloading and/or compression recommendations.~* ABI = or \>0.8 if the wound is located on a lower extremity.~* Wound has the presence of callus requiring sharp or surgical debridement within 3 days prior to randomization and/or needs debridement using any method other than the study agent throughout study treatment.~* Subject has medical instability as deemed by the investigator.~* Subject is pregnant.~* Subject has participated in another clinical trial or wound dressing evaluation in the 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collagenase (Type: ACTIVE_COMPARATOR): This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
- Active leptospermum honey (Type: ACTIVE_COMPARATOR): This is an active medicinal grade honey used to promote autolytic debridement and applied daily

Based on this trial design, predict the completion outcome and termination type (if applicable).